AKT2 and hepatocellular carcinoma: JIB-04 interfered with the cell cycle progression of HCC cells and cancer stem-like cell properties via the AKT2-FOXO3a-RB axis by inhibiting the histone demethylase activity of KDM6B on the AKT2 promoter.